2016 was an important year for cancer control in China. This report presents the progress and achievements in cancer prevention including environment management,smoking control, obesity prevention, health insurance of serious illness, annual check-up; the major achievements in the treatment of lung cancer, leukemia, breast cancer, gistrointestinal cancer and nasopharrengeal cancer; as well as developments of new anticancer agents, immune treatment and construction of translational research platforms. The perspective of cancer prevention and treatment in the near future is also briefly discussed.
SHI Yuankai
,
YANG Sheng
,
SUN Yan
. Glance back of China's cancer control and treatment in 2016[J]. Science & Technology Review, 2017
, 35(1)
: 96
-99
.
DOI: 10.3981/j.issn.1000-7857.2017.01.011
[1] (NCD-RisC) NRFC. Trends in adult body-mass index in 200 countries from 1975 to 2014:A pooled analysis of 1698 population-based measurement studies with 19.2 million participants[J]. Lancet, 2016, 387(10026):1377-1396.
[2] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] Shi Y, Wang L, Han B, et al. First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE)[J]. J Clin Oncol, 2016, 34(Suppl):Abstr 9041.
[4] Cheng Y. Randomized phase ii trial of gifitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth receptor mutations[J]. J Clin Oncol, 2016, 34(27):3258-3266.
[5] Wu Y. BRAIN:A phase-trial comparing wbi and chemotherapy with icotinib in NSCLC with Brain metastases harboring EGFR mutations[C]//17th World Conference on Lung Cancer (WCLC). 2016:Abstract PL03.05.
[6] Dai C. Choice of surgical procedure for patients with non-small-cell lung cancer≤1 cm or >1 to 2 cm among lobectomy, segmentectomy, and wedge resection:A population-based study[J]. J Clin Oncol, 2016, 34(26):3175-82.
[7] Harbeck N, Huang C S, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1):An open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(3):357-366.
[8] Xu B, Sun T, Zhang Q, et al. Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment[C]//2016 American Society of Clinical Oncology (ASCO). 2016:Abstract 1004.
[9] Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1450.
[10] Qin S, Xu J, Wang L, et al. LBA-05:First-line FOLFOX-4±cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC):The open-label, randomized phase 3 TAILOR trial[J]. Annals of Oncology, 2016, 27(Suppl 2):ii141.
[11] Zhang L. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054):1883-1892.
[12] Yihebali C, Sun Y, J, Cai J, et al. Phase II study of anlotinib for treatment of advanced softtissues sarcomas[C]//2016 American Society of Clinical Oncology(ASCO). 2016:Abstract 11005.
[13] Mok T S. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer[J]. N Engl J Med, 2016-12-06[Epub ahead of print].
